SCHEMBL24264671

SCHEMBL24264671

CCP(=O)(O)O[C@H]1CC[C@H](C(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCON)C(=O)NCCOCCON)C(=O)NCCOCCON)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.43
▸ POLB P06746 1/20 0.34
▸ TLR2 O60603 2/20 0.32
▸ PLG P00747 2/20 0.32
▸ PRSS1 P07477 2/20 0.32
▸ PRSS2 P07478 2/20 0.32
▸ PRSS3 P35030 2/20 0.32
▸ PLAU P00749 1/20 0.32
▸ LPAR3 Q9UBY5 2/20 0.32
▸ CHRNA1 P02708 1/20 0.31
▸ CHRNG P07510 1/20 0.31
▸ CHRNB1 P11230 1/20 0.31
▸ CHRND Q07001 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ CCKAR P32238 1/20 0.31
▸ CCKBR P32239 1/20 0.31
▸ GRIN1 Q05586 1/20 0.30
▸ GRIN2A Q12879 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23869978 1.00 GLP1R (0.43) GLP1RPOLBTLR2PLGPRSS1
SCHEMBL22453609 0.95 GLP1R (0.39) GLP1RPOLBTLR2PLGPRSS1
SCHEMBL20375531 0.91 GLP1R (0.43) GLP1RPOLBTLR2PLGPRSS1
SCHEMBL18715377 0.91 GLP1R (0.43) GLP1RPOLBTLR2PLGPRSS1
SCHEMBL18715404 0.91 GLP1R (0.43) GLP1RPOLBTLR2PLGPRSS1
SCHEMBL24479569 0.91 GLP1R (0.43) GLP1RPOLBTLR2PLGPRSS1
SCHEMBL24264573 0.90 GLP1R (0.43) GLP1RPOLBPLGPRSS1PRSS2
SCHEMBL23870009 0.90 GLP1R (0.43) GLP1RPOLBPLGPRSS1PRSS2
SCHEMBL20800932 0.90 GLP1R (0.43) GLP1RPOLBTLR2PLGPRSS1
SCHEMBL20375384 0.89 GLP1R (0.41) GLP1RPOLBTLR2PLGPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220056454-A1 RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2022-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220056454-A1 RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use HSD17B13, HSD17B3, HSD17B10 GLP1R 3037/4885POLB 1324/4885TLR2 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback